MAPT and Alzheimer disease: At baseline, as well as after one and 2 years, CSF Aβ43 with or without t-tau in the equation separated patients with aMCI not progressing to AD within the 2 years of study from patients that did progress to AD, as well as from those diagnosed with AD at baseline.